Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial

dc.creatorCostanza, Annelise C
dc.creatorMoscavitch, Samuel D
dc.creatorFaria Neto, Hugo C. C
dc.creatorMesquita, Evandro T
dc.date2015-05-27T13:39:52Z
dc.date2015-05-27T13:39:52Z
dc.date2015
dc.date.accessioned2023-09-26T20:10:23Z
dc.date.available2023-09-26T20:10:23Z
dc.identifierCOSTANZA, Annelise C. et al. Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial. International Journal of Cardiology, v.179, p.348–350, 2015.
dc.identifier0167-5273
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/10555
dc.identifier10.1016/j.ijcard.2014.11.034
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8850395
dc.descriptionOn the last decade, there has been a progressive increase in a number of publications on microbiota and therapeutic potential of probiotics. Recent studies have been suggesting that consuming probiotics may have benefits on cardiovascular system, as the improvement on blood pressure control by a modest degree [1]. Heart failure (HF) patients present low grade inflammation that participates on the progression of cardiac remodeling [2]. Moreover, when the heart is failing, myocytes show enhanced expression of inflammatory mediators, as adhesion molecules, tumor necrosis factor (TNF)-a, interleukin-6 and others [2].
dc.descriptionJan. 2016
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsrestricted access
dc.subjectHeart
dc.subjectFailure
dc.subjectProbiotic
dc.subjectMicrobiota
dc.subjectInflammation
dc.subjectSystolic
dc.subjectSístole
dc.subjectInflamação
dc.subjectMicrobiota
dc.subjectCoração
dc.subjectInsuficiência Cardíaca Sistólica
dc.titleProbiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial
dc.typeArticle


Este ítem pertenece a la siguiente institución